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The genetics and epidemiology of generalized 
vitiligo
Generalized vitiligo (GV) is the most common depig-
mentation disorder, in which acquired multifocal patches 
of white skin and overlying hair result from loss of 
melanocytes in the involved areas (Figure 1) [1,2]. Th  e 
prevalence of GV is approximately 0.5% in various 
populations [3], with an average age of onset at about 
24  years and occurring with approximately equal fre-
quency in males and females [4]. Th   e concordance of GV 
in monozygotic twin-pairs is approximately 23% [4], and 
epidemiological evidence indicates that GV is a complex 
trait involving multiple genes and unknown environ-
mental factors [3].
Many hypotheses have been proposed to account for 
melanocyte loss in GV [1]. Most current evidence 
supports an autoimmune basis of disease [5], though the 
triggers of the autoimmune response remain unknown. 
Among European-derived white individuals with GV, 
about 15% to 25% have at least one additional conco  mitant 
autoimmune disease, particularly autoimmune thyroid 
disease (Hashimoto’s thyroiditis and Graves’ disease), 
pernicious anemia, rheumatoid arthritis, psori  asis, type 1 
diabetes, Addison’s disease and systemic lupus erythe  ma-
tosus; these diseases also occur at increased frequencies 
in ﬁ  rst-degree relatives of patients with GV, whether or 
not those relatives have GV them  selves [4]. Together, 
these ﬁ  ndings indicate that patients with GV and their 
close relatives have inherited susceptibility to this speciﬁ  c 
diathesis of autoimmune diseases, mediated by shared 
susceptibility genes.
Vitiligo susceptibility genes
Candidate gene association studies and gene expression 
analyses have produced a long list of GV candidate genes, 
of which only HLA (human leukocyte antigen) and 
PTPN22 (protein tyrosine phosphatase, non-receptor type 
22) have had consistent support from multiple studies; 
most of the rest are likely to represent false positives 
[3,6]. Two additional genes, NALP1 (now NLRP1; NLR 
family, pyrin domain containing 1) and XBP1 (X-box 
binding protein 1), were ﬁ   rst mapped by unbiased 
genome-wide linkage analyses and subsequently were 
identiﬁ   ed by positionally targeted genetic association 
studies [7,8]; both of these genes have subsequently been 
replicated by multiple studies [3,6]. Th   ese four conﬁ  rmed 
GV susceptibility loci - HLA, PTPN22, NLRP1 and XBP1 - 
all encode important immunoregulatory proteins, 
lending support to the autoimmune hypothesis of GV 
pathogenesis.
Recently, three diﬀ   erent genome-wide association 
studies (GWASs) of GV have been reported: two from 
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China [12]. Together, these studies identiﬁ  ed a total of 17 
conﬁ  rmed GV susceptibility loci, yielding major insights 
into pathways of disease pathogenesis and overall 
strongly supporting an autoimmune basis for typical GV. 
Th  e ﬁ  rst GWAS, of a founder population in an isolated 
Romanian village with a high prevalence of GV and other 
autoimmune diseases [9], detected association at chromo-
some 6qter near IDDM8, which is a type 1 diabetes-
rheumatoid arthritis locus in the vicinity of SMOC2 
(SPARC-related modular calcium binding 2). Th  e  second 
GWAS [10,11], also carried out in European-derived 
white individuals, identiﬁ  ed a total of 13 susceptibility 
loci for GV, including HLA class I (speciﬁ  cally, 
HLA-A*0201),  HLA class II, PTPN22,  RERE (arginine-
glutamic acid dipeptide repeats), FOXP1 (forkhead box 
P1), LPP (LIM domain containing preferred translocation 
partner in lipoma), CCR6 (chemokine (C-C motif) recep-
tor 6), IL2RA  (interleukin 2 receptor, α), TYR,  GZMB 
(granzyme B), NLRP1,  UBASH3A  (ubiquitin-associated 
and SH3 domain containing A) and C1QTNF6 (C1q and 
tumor necrosis factor related protein 6). Moreover, 
subsequent re-analysis of this genome-wide dataset to 
speciﬁ   cally test association of 33 biological candidate 
genes previously implicated in GV identiﬁ  ed  three 
additional GV susceptibility loci: TSLP (thymic stromal 
lymphopoietin), XBP1 and FOXP3 (forkhead box P3) [6]. 
Th  e third GWA study [12], carried out in a Chinese 
population, also identiﬁ  ed GV susceptibility loci in the 
HLA class I and class III regions, and likewise detected 
association with CCR6. Moreover, the GV-associated 
SNP in the CCR6 region is the same in European-derived 
white individuals and Chinese people, suggesting that 
these two populations may share a single causal allele, 
and is located only 1.44 Mb from the previous GV-
associated SNP in the SMOC2 region [9], suggesting the 
possibility that these two signals might be related. 
Virtually all of the conﬁ   rmed GV susceptibility loci 
encode known immunoregulatory proteins, and many 
have been associated with genetic susceptibility to other 
autoimmune diseases that are epidemiologically linked to 
GV (Figure 2).
Th   e one exception among the susceptibility loci 
associated with GV is TYR, which encodes tyrosinase, 
the key enzyme of melanin biosynthesis in melanocytes. 
However, in GV even TYR may act primarily to modulate 
recognition of the melanocyte target cell by the immune 
system. Beyond its role in pigmentation, tyrosinase is the 
major autoantigen in GV. In this regard, GV is thus 
analogous to type 1 diabetes and autoimmune thyroid 
disease, in that genetic susceptibility to disease involves 
genes that encode key specialized intracellular compo-
nents of the autoimmune target cell types and that con-
stitute major autoantigens for the corresponding disease 
(GV:  TYR, tyrosinase; type 1 diabetes: INS, insulin; 
autoimmune thyroid disease: TG, thyroglobulin). For GV, 
the causal TYR susceptibility variant appears to be the 
major (Arg) allele of rs1126809, a common non-synony-
mous (Arg402Gln) polymorphism that has a minor allele 
frequency of 0.22 to 0.40 in European-derived white 
individuals. Th   is polymorphism is rare in other popula-
tions, which is why it was not detected in the Chinese 
GWAS, even though TYR may well play a role in GV 
pathogenesis in all populations. In contrast, the minor 
(Gln) allele, which is protective with respect to GV, is 
associated with susceptibility to malignant melanoma in 
European-derived white individuals [13,14]. Th  us, from 
the standpoint of genetic susceptibility, the TYR 
Arg402Gln polymorphism represents an inverse relation-
ship between GV and malignant melanoma.
Much of the biology that is likely to underlie this 
inverse relationship is already known, largely from 
extensive studies on melanoma patients, in whom GV 
may develop during the course of treatment and is an 
auspicious prognostic sign. Tyrosinase is a major antigen 
Figure 1. A patient with generalized vitiligo. Note the typical 
pattern of bilateral, multifocal depigmentation of hands and 
periorbital regions.
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melano  cytes and melanoma cells by HLA class I mole-
cules, principally HLA-A*0201, which itself is a major GV 
risk allele. Indeed, HLA-A*0201 and TYR 402Arg exhibit 
signiﬁ  cant genetic interaction in promoting GV suscep-
tibility [10], reﬂ  ecting a corresponding biological inter-
action. One of the important class-restricted epitopes 
presented by HLA-A*0201 is a speciﬁ  c modiﬁ  ed tyro-
sinase peptide: YMDGTMSQV [15]. However, the TYR 
402Gln variant results in an unstable polypeptide that is 
retained in the endoplasmic reticulum and degraded, 
thereby reducing the amount of tyrosinase peptide 
available for presentation on the cell surface. Moreover, 
presentation of this tyrosinase peptide by HLA-A*0201 
requires the posttranslational modiﬁ   cation of residue 
371Asn to Asp [15], via a mechanism that is probably 
ineﬃ   cient in the TYR 402Gln polypeptide. Tyrosinase is 
thus an important signal by which the immune system 
recognizes melanocytes, and tyrosinase-402Arg is likely 
to make a greater contribution than tyrosinase-402Gly to 
immune surveillance (and thus protection) against 
malignant melanoma and to susceptibility to GV, whereas 
tyrosinase-402Gln is associated with lower susceptibility 
to GV but greater risk of melanoma. Indeed, the odds 
ratio for vitiligo susceptibility is 2.5 in TYR 402Arg 
homozygotes compared to 402Gln homozygotes (10).
Interestingly, two of the other GV susceptibility loci, 
IL2RA and GZMB, encode proteins involved in diﬀ  eren-
tiation and eﬀ  ector functions of cytotoxic T lymphocytes 
(CTLs) that mediate melanocyte killing in GV and 
perhaps also participate in immune surveillance for mela-
noma cells. Th  us, at least four of the GV genome-wide 
association signals - HLA class I (HLA-A*0201),  TYR 
402Arg, IL2RA and GZMB - may be part of a pathway by 
which CTLs recognize and ultimately kill melanocytes in 
patients with GV, and perhaps also protect against 
incipient melanomas.
Th   ese observations open several doors to future 
studies. In GV, it has been known for some time that 
patients have circulating skin-homing melanocyte-speciﬁ  c 
CTLs [16]. However, the molecular epitopes recognized 
by these melanocyte-speciﬁ   c CTLs have not yet been 
identiﬁ  ed. At least in GV patients carrying HLA-A*0201, 
one of these CTL epitopes might be the modiﬁ  ed 
tyrosinase peptide YMDGTMSQV. Furthermore, it is not 
yet known whether susceptibility to GV is generic with 
respect to HLA-A*0201 (which is quite common), or 
whether it is particular to speciﬁ  c subtypes, and whether 
those subtypes conversely confer the greatest protection 
against melanoma.
Conclusions and perspectives
Recent GWASs have yielded substantial progress in 
identi  fying genes involved in risk of GV, with 17 loci now 
conﬁ  rmed  (HLA class I, HLA class II, HLA class III, 
PTPN22, RERE, FOXP1, LPP, TSLP, CCR6, IL2RA, TYR, 
GZMB,  NLRP1,  UBASH3A,  XBP1,  C1QTNF6, and 
FOXP3): 16 in European-derived white individuals and 
Figure 2. Genetic relationships of generalized vitiligo susceptibility genes and other autoimmune diseases. Circles indicate loci associated 
with susceptibility to a given autoimmune disease: yellow, shared risk alleles; orange, opposite risk alleles at same SNP; white, secondary association 
due to primary association with autoimmune disease epidemiologically associated with generalized vitiligo. SLE, systemic lupus erythematosus.
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Nevertheless, the 16 loci identiﬁ  ed in European-derived 
white individuals together account for only 10% of the 
total genetic risk of GV in that group, indicating that 
additional loci probably remain to be discovered, with a 
few common and perhaps numerous rare variants 
accounting for disease risk at each locus. Essentially all of 
the conﬁ  rmed GV susceptibility genes regulate function 
of the immune system, and many have also been 
associated with other autoimmune diseases, highlighting 
shared pathways of autoimmune susceptibility among 
these diseases.
Furthermore, ﬁ   ndings for both HLA-A and TYR 
suggest an inverse relationship between susceptibility to 
GV and susceptibility to malignant melanoma, with 
genetic interaction that reﬂ  ects underlying biochemical 
and functional interaction between the corresponding 
proteins. Th   e overall picture indicates that genetic varia-
tion at HLA-A*0201 and TYR interacts to modulate 
immune surveillance against malignant melanoma, with 
heightened surveillance predisposing to GV and protect-
ing against melanoma, and reduced surveillance protect-
ing against GV but predisposing to melanoma. Th  is 
biological relationship may also explain the frequent 
occur  rence of GV in patients treated for melanoma, in 
whom development of this autoimmune phenotype 
consti  tutes a relatively favorable prognostic sign.
While these discoveries underscore the autoimmune 
nature of GV, they do not oﬀ  er speciﬁ  c clues as to the 
environmental triggers that may initiate the autoimmune 
response. GV is a disease of the skin, the organ that is the 
ﬁ   rst point of contact for one’s interaction with the 
external environment, and which is highly accessible for 
analysis of that interaction. Furthermore, because GV is 
so visually evident, it is usually diagnosed early. Th  us, 
identiﬁ   cation of GV susceptibility genes may enable 
identiﬁ  cation of individuals at high genetic risk, enabling 
relatively direct analysis of potentially causal gene-
environment interactions, both retrospectively in 
patients with relatively recent disease onset, and prospec-
tively in individuals who are at high genetic risk.
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